Introduction: Long-acting bronchodilators are pivotal in the therapeutic management of COPD patients with moderate-to-severe airflow obstruction. New ultra-long-acting beta 2-agnoists (ultra-LABAs) have been developed, some of which have been licensed for use as monotherapy and/or in combination with other bronchodilators or inhaled corticosteroids, for use in COPD patients with persistent symptoms and worsening airflow limitation. These new agents are faster in onset and have a prolonged duration of action, with a similar safety profile to the traditional twice-daily bronchodilators which may have an impact on patient concordance.Areas covered: A number of these ultra-LABAs are still under development and bi-functional hybrid molecules containing regions functioning as beta 2-agonists, and as muscarinic agonists (MABAs) has been developed. This review summarizes these (excluding the licensed ultra-LABAs) with attention on phase II studies data available to-date on their pharmacological profiles, clinical efficacy and safety, and future perspectives.Expert opinion: Despite all the new agents' available, the challenges that persist include any differences in efficacy and safety between the various possible LAMA/LABA combinations, relative advantages of MABAs over fixed-dose LAMA/LABAs, and the impact of these new molecules in terms of long term safety, especially in certain populations in co-morbidities frequently associated with COPD.

Malerba, M., Radaeli, A., Montuschi, P., Babu, K. S., Morjaria, J. B., Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease, <<EXPERT OPINION ON INVESTIGATIONAL DRUGS>>, 2017; 26 (3): 319-329. [doi:10.1080/13543784.2017.1287172] [https://hdl.handle.net/10807/222546]

Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease

Montuschi, Paolo;
2017

Abstract

Introduction: Long-acting bronchodilators are pivotal in the therapeutic management of COPD patients with moderate-to-severe airflow obstruction. New ultra-long-acting beta 2-agnoists (ultra-LABAs) have been developed, some of which have been licensed for use as monotherapy and/or in combination with other bronchodilators or inhaled corticosteroids, for use in COPD patients with persistent symptoms and worsening airflow limitation. These new agents are faster in onset and have a prolonged duration of action, with a similar safety profile to the traditional twice-daily bronchodilators which may have an impact on patient concordance.Areas covered: A number of these ultra-LABAs are still under development and bi-functional hybrid molecules containing regions functioning as beta 2-agonists, and as muscarinic agonists (MABAs) has been developed. This review summarizes these (excluding the licensed ultra-LABAs) with attention on phase II studies data available to-date on their pharmacological profiles, clinical efficacy and safety, and future perspectives.Expert opinion: Despite all the new agents' available, the challenges that persist include any differences in efficacy and safety between the various possible LAMA/LABA combinations, relative advantages of MABAs over fixed-dose LAMA/LABAs, and the impact of these new molecules in terms of long term safety, especially in certain populations in co-morbidities frequently associated with COPD.
2017
Inglese
Malerba, M., Radaeli, A., Montuschi, P., Babu, K. S., Morjaria, J. B., Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease, <<EXPERT OPINION ON INVESTIGATIONAL DRUGS>>, 2017; 26 (3): 319-329. [doi:10.1080/13543784.2017.1287172] [https://hdl.handle.net/10807/222546]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/222546
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact